Ayala Pharmaceuticals, Inc. (ADXS) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Monmouth Junction, NJ, United States. The current CEO is Kenneth A. Berlin.
ADXS has IPO date of 2020-05-08, 20 full-time employees, listed on the Other OTC, a market capitalization of $25.71M.
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.
